

FINAL PROGRAM

XVII NIBIT MEETING

**Oncology embraces immunology:
the way forward**



www.nibit.org

Verona, October 11-13, 2019

NIBIT SCIENTIFIC COMMITTEE

Matteo Bellone (Milano, Italy)
Marco Bregni (Milano, Italy)
Vincenzo Bronte (Verona, Italy)
Mario Paolo Colombo (Milano, Italy)
Massimo Di Nicola (Milano, Italy)

Pier Francesco Ferrucci (Milano, Italy)
Paola Nisticò (Roma, Italy)
Antonio Rosato (Padova, Italy)
Vincenzo Russo (Milano, Italy)
Antonio Sica (Milano, Italy)

LOCAL SCIENTIFIC COMMITTEE

Vincenzo Bronte (Verona, Italy)
Stefania Gori (Verona, Italy)

Michele Milella (Verona, Italy)
Aldo Scarpa (Verona, Italy)

FACULTY

Ranjana Advani - Stanford Cancer Institute (Stanford, USA)
Andrea Alimonti - Institute of Oncology Research IOR (Bellinzona, Switzerland)
Martina Angi - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Claudio Bassi - Verona Pancreas Institute (Verona, Italy)
Matteo Bellone - IRCCS Ospedale San Raffaele (Milano, Italy)
Federica Benvenuti - ICGEB International Centre for Genetic Engineering and Biotechnology (Trieste, Italy)
Christian Blank - Nederlands Kanker Instituut (Amsterdam, The Netherlands)
Roberto Bordonaro - Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione GARIBALDI (Catania, Italy)
Marco Bregni (Milano, Italy)
Vincenzo Bronte - Università degli Studi di Verona (Verona, Italy)
Luigi Buonaguro - Istituto Nazionale per la Cura dei Tumori "Fond. Pascale" (Napoli, Italy)
Marco Cassatella - Università degli Studi di Verona (Verona, Italy)
Triantafyllos Chavakis - Universitätsklinikum Carl Gustav Carus (Dresden, Germany)
Fabio Ciceri - IRCCS Ospedale San Raffaele (Milano, Italy)
Emilia Cocorocchio - Istituto Europeo di Oncologia - IEO (Milano, Italy)
Mario Paolo Colombo - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Ruggero De Maria - Università Cattolica del Sacro Cuore (Roma, Italy)
Sandra Demaria - Weill Cornell Medicine (New York, USA)
Serena Di Cosimo - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Massimo Di Nicola - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Pier Francesco Ferrucci - Istituto Europeo di Oncologia - IEO (Milano, Italy)
Carl Figdor - Radboud University (Nijmegen, Netherlands)
Gaetano Finocchiaro - Fondazione IRCCS Istituto Neurologico Carlo Besta (Milano, Italy)

Wolf Herman Fridman - Université Paris Descartes (Paris, France)
Enzo Galligioni - Fondazione Pezcoller (Trento, Italy)
Marina Garassino - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Luca Gattinoni - NIH National Cancer Institute (Bethesda, USA)
Stefania Gori - Ospedale Sacro Cuore Don Calabria (Negrar - VR, Italy)
Massimo Guidoboni - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (Meldola - FC, Italy)
Sophie Lucas - de Duve Institute - UCLouvain (Bruxelles, Belgium)
Nicholas McGranahan - University College London (London, UK)
Ignacio Melero - Clinica Universidad de Navarra (Navarra, Spain)
Michele Milella - Università degli Studi di Verona (Verona, Italy)
Paola Nisticò - IFO Istituto Regina Elena (Roma, Italy)
Jill O'Donnell-Tormey - Cancer Research Institute (New York, USA)
Maria Pia Protti - IRCCS Ospedale San Raffaele (Milano, Italy)
Antonio Rosato - Università degli Studi di Padova (Padova, Italy)
Vincenzo Russo - IRCCS Ospedale San Raffaele (Milano, Italy)
Sriram Sathy - Codiak Biosciences (Cambridge, USA)
Catherine Sautès-Fridman - UPMC Sorbonne Université (Paris, France)
Aldo Scarpa - Università degli Studi di Verona (Verona, Italy)
Padmanee Sharma - MD Anderson Cancer Centre (Houston, USA)
Antonio Sica - Istituto Clinico Humanitas (Rozzano - MI, Italy)
Gabriella Sozzi - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Elda Tagliabue - IRCCS Istituto Nazionale dei Tumori (Milano, Italy)
Catia Traversari - MolMed S.p.A. (Milano, Italy)

12:30 Registrations and Light Lunch

13:45 Welcome addresses

SESSION 1 - TUMOR MICROENVIRONMENT (NIBIT-SIICA JOINT SESSION)

Chairs: Marco Cassatella & Vincenzo Russo

14:00 **Wolf-Herman Fridman (Paris, France)**

Context dependent impact of B cells on cancer clinical outcome

14:25 **Sophie Lucas (Bruxelles, Belgium)**

Targeting GARP on human Tregs: a novel approach for the immunotherapy of cancer?

14:50 **Triantafyllos Chavakis (Dresden, Germany)**

Innate immune training in tumor immunotherapy

INVITED ABSTRACT

15:15 **Catherine Sautes-Fridman (Paris, France)**

Tertiary lymphoid structures at the era of cancer immunotherapy

SELECTED ABSTRACTS

15:30 **Silvia Picones (Sapienza Università di Roma, Italy)**

Regulatory T cells oscillate between a TNF-producing and a TNFR2-expressing status, and TNF-TNFR2 positive loop sustains Treg proliferation in cancer

15:45 **Francesca Di Modugno (IFO - Istituto Regina Elena - Roma, Italy)**

hMENA isoforms inversely regulate the expression of lymphotoxin β receptor in tumor cells and CAFs, influencing the tertiary lymphoid structure localization and the prognosis of early node-negative non-small cell lung cancer patients

16:00 **Coffee break**

SESSION 2 - ANTIGEN PRESENTING CELLS & ACTIVE IMMUNOTHERAPY

Chairs: Paola Nisticò & Massimo Di Nicola

16:30 **Carl Figdor (Nijmegen, The Netherlands)**

Synthetic immune systems to outsmart cancer

16:55 **Nicholas McGranahan (London, UK)**

The interplay between lung cancer genome evolution and the immune microenvironment

17:20 **Gaetano Finocchiaro (Milano, Italy)**

Dendritic cells, checkpoint inhibitors and the glioblastoma microenvironment

INVITED ABSTRACT

17:45 **Federica Benvenuti (Trieste, Italy)**

The tumor microenvironment inhibits DCs efferocytosis by TIM4 and tumor-antigen cross priming

SELECTED ABSTRACTS

18:00 **Mattia Lauriola (Università di Bologna, Italy)**

Neutralizing interleukin 1 axis to overcome resistance to EGFR targeting antibody

18:15 **Barbara Bassani (IRCCS Istituto Nazionale dei Tumori - Milano, Italy)**

The role of Zeb-1 in acute myeloid leukaemia

18:30 **General Assembly of the NIBIT**

19:30 **Welcome Wine, Cheese & Poster Viewing**

SESSION 3 - ADOPTIVE IMMUNOTHERAPY (NIBIT-ACC JOINT SESSION)*Chairs: Ruggero De Maria & Antonio Rosato*

- 09:00 **Fabio Ciceri (Milano, Italy)**
CAR-T cells in hematologic malignancies
- 09:25 **Catia Traversari (Milano, Italy)**
The CD44V6 CAR for the treatment of hematopoietic and solid cancers
- 09:50 **Luca Gattinoni (Bethesda, USA)**
CD19-specific CAR CD8+ memory stem cells for the treatment of human B-cell malignancies

SELECTED ABSTRACTS

- 10:15 **Francesco De Sanctis (Università degli Studi di Verona, Italy)**
The nitrosative stress modulation of pancreatic tumor microenvironment favors the immune attack of TERT specific cytotoxic T lymphocytes
- 10:30 **Gaia Zuccolotto (Università degli Studi di Padova, Italy)**
Anti-PSMA CAR Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Prostate Cancer Cells
- 10:45 **Coffee break**

SESSION 4 - MODULATING IMMUNOTHERAPY IN SOLID TUMORS (NIBIT-SIC JOINT SESSION)*Chairs: Antonio Sica & Gabriella Sozzi*

- 11:00 **Ranjana Advani (Stanford, USA)**
The first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab in relapsed/refractory lymphoma
- 11:25 **Sandra Demaria (New York, USA)**
Effects of radiation on tumor antigenicity and adjuvanticity: from mice to patients and back
- 11:50 **Marina Garassino (Milano, Italy)**
Combination Therapies in stage III-IV NSCLC
- 12:15 **Ignacio Melero (Navarra, Spain)**
On evil and virtuous cytokines in cancer immunotherapy

SELECTED ABSTRACT

- 12:40 **Marino Kallikourdis (Istituto Clinico Humanitas – Rozzano | MI, Italy)**
Dissecting the tissue-independent, context-dependent distinct roles of type 2-polarized responses in carcinogenesis versus tumor growth reveals surprising insights for optimizing the timing of tumor immunotherapy in patients.
- 13:00 **Lunch & Poster Viewing**

SESSION 5 - MODULATING IMMUNOTHERAPY IN MELANOMA AND OTHER IMMUNE SENSITIVE TUMORS*Chairs: Matteo Bellone & Marco Bregni*

- 14:15 **Elda Tagliabue (Milano, Italy)**
Commensal gut microbiota influences efficacy of trastuzumab in patients with HER2 – positive breast carcinoma
- 14:40 **Christian Blank (Amsterdam, The Netherlands)**
Neoadjuvant immunotherapy: the pathway to personalized immunotherapy
- 15:05 **Pier Francesco Ferrucci (Milano, Italy)**
Triplet therapy with antiBRAF/MEK and antiPD1: rationale and clinical outcome

SELECTED ABSTRACTS

- 15:30 **Luna Minute (CIMA-Universidad de Navarra, Spain)**
Cellular cytotoxicity is a form of immunogenic cell death
- 15:45 **Maria Teresa Majorini (IRCCS Istituto Nazionale dei Tumori – Milano, Italy)**
Role of infiltrating mast cells in affecting the clinical outcome of HER2-positive breast cancer patients
- 16:00 **Marta Truffi (Istituti Clinici Scientifici Maugeri IRCCS – Pavia, Italy)**
Trastuzumab nanoconjugation on iron oxide nanoparticles increases drug responsiveness in sensitive and resistant breast cancer cell lines
- 16:15 **Coffee break**
- 16:40 **Jill O'Donnell-Tormey (New York, USA)**
Vision, persistence, impact: a Nonprofits' role in shaping immuno-oncology

PEZCOLLER KEYNOTE LECTURE

Chairman: Mario P. Colombo

- 17:00 **Enzo Galligioni (Verona, Italy)**
The Pezcoller Foundation
- 17:10 **Padmanee Sharma (Houston, USA)**
From the clinic to the lab: investigating response and resistance mechanisms to immune checkpoint therapy
- 18:15 **Poster Viewing**
- 20:00 **Social Dinner – Palazzo Verità Poeta**

Final program

Sunday, October 13

SESSION 6 - FOCUS ON PANCREATIC ADENOCARCINOMA AND OTHER IMMUNE RESISTANT TUMORS

Chairs: Vincenzo Bronte & Michele Milella

- 09:00 **Aldo Scarpa (Verona, Italy)**
A common platform for next generation diagnosis of solid tumors
- 09:25 **Maria Pia Protti (Milano, Italy)**
Mechanisms of immune deviation in pancreatic adenocarcinoma
- 09:50 **Andrea Alimonti (Bellinzona, Switzerland)**
Molecular drivers in castration-resistant prostate cancer

INVITED ABSTRACT

- 10:15 **Claudio Bassi (Verona, Italy)**
Multimodality in pancreatic cancer treatment: are we really going better?

SELECTED ABSTRACT

- 10:15 **Paola Cappello (Università degli Studi di Torino, Italy)**
Combined IL17 depletion and DNA vaccination efficiently elicits an anti-tumor response in pancreatic cancer
- 10:45 **Coffee break**

SESSION 7 - CLINICAL AND RESEARCH HIGHLIGHTS AROUND NIBIT (NIBIT-AIOM Joint Session)

Chairs: Mario P. Colombo & Stefania Gori

- 11:00 **Roberto Bordonaro (Catania, Italy)**
Currently ongoing trials with immuno-checkpoint inhibitors
- 11:20 **Massimo Guidoboni (Meldola, Italy)**
Dendritic cell vaccines in 2019: new tricks from an old dog?
- 11:40 **Luigi Buonaguro (Naples, Italy)**
Cancer vaccine development for liver cancer
- 12:00 **Serena Di Cosimo (Milano, Italy)**
Immunomodulatory effect of cyclin kinase inhibitors in breast cancer

WHAT'S IN THE PIPELINE? (NON CME SESSION)

- 12:20 **Sriram Sathy (Cambridge, USA)**
Developing and engineered exosome therapeutic platform for Immuno-Oncology
- 12:35 **Emilia Cocorocchio (Milano, Italy)**
Novel approaches in the treatment of locally advanced melanoma
- 12:50 **Martina Angi (Milano, Italy)**
Novel approaches in the treatment of uveal melanoma
- 13:05 **NIBIT Awards Nominations**
- 13:30 **Adjourn**

CONGRESS VENUE

CAMERA DI COMMERCIO INDUSTRIA ARTIGIANATO AGRICOLTURA VERONA

Corso Porta Nuova, 96 - 37122 Verona

HOW TO BECOME A NIBIT MEMBER

If you wish to **become a member of NIBIT Association**, please visit

<http://nibit.org/iscrizioni.php> - The rate is € 50,00 / year

If you pay the annual fee before registration, you are entitled to the NIBIT MEMBER Fee rate.

CONGRESS REGISTRATION FEES

NIBIT Member - over 35 years	€ 150,00 VAT included
NIBIT Member - under 35 years	free of charge
PhD Student	free of charge
Resident	free of charge
Student	free of charge
NIBIT Non-Member - over 35 years	€ 230,00 VAT included
NIBIT Non-Member - under 35 years	€ 230,00 VAT included

SOCIAL DINNER

The Social Dinner will be held on October 12, 2019 at Palazzo Verità-Poeta. The attendance is open to all registered participants to the XVII NIBIT Meeting with the following criteria:

- **€ 30,00 VAT INCLUDED** for NIBIT Members under 35 years, PhD Students,

Residents and Students

- **FREE OF CHARGE** for registered NIBIT Member over 35 years and Non-Member.

Please specify if you wish to attend and if not done yet, please confirm your participation to the staff at the registration desk at the congress venue.

C.M.E. ACCREDITATION

Provider: MZ CONGRESSI - ID 966

The Congress was granted **9,1 C.M.E. credits** from the Italian Ministry of Health for the following specialties: **Physicians** specialized in allergology and clinical immunology, pathological anatomy, clinical biochemistry, general surgery, thoracic surgery, palliative care, dermatology and venerology, hematology, general practice medicine, internal medicine, oncology, radiotherapy. **Biologists. Biomedical laboratory technician.**

ORGANISING SECRETARIAT



Achelois - Professional Congress Organiser

Via Larga 8 - 20122 Milano

Tel. 02 2643 6227

e-mail: linda.isella@achelois.eu

ACHELOIS - Professional Congress Organiser



Acknowledgments

GOLD



SILVER



BRONZE



PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON

Una Divisione Pierre Fabre Pharma

STANDARD

